Skip to main navigation
Axsome Corporate Homepage
  • About Axsome
    • All
    • Overview
    • Management Team
    • Board of Directors
    • Intellectual Property
    • State Disclosures
  • Portfolio
    • All
    • Overview
    • Products Overview  down arrow
      • All
      • Overview
      • Auvelity® (dextromethorphan-bupropion)
      • Sunosi® (solriamfetol)
      • Symbravo® (meloxicam and rizatriptan)
    • Pipeline Overview  down arrow
      • All
      • Overview
      • AXS-05
      • AXS-12
      • AXS-14
  • Conditions
    • All
    • Overview
    • Depression
    • Migraine
    • Alzheimer’s Disease Agitation
    • Excessive Daytime Sleepiness
    • Narcolepsy
    • Fibromyalgia
    • Smoking Cessation
  • Axsome Corporate Homepage
  • Science
    • All
    • Overview
    • Medical Information U.S.
    • Medical Information Canada
    • Publications
  • Investors
    • All
    • Overview
    • Corporate Governance
    • Stock Information
    • Financial Information
    • News & Events
    • Webcasts & Presentations
    • Analyst Coverage
    • Shareholder Services
  • Careers
    • All
    • Overview
    • Current Opportunities

SEC Filing Details

SEC Filing
Details

SEC Filing Details

SEC Filing Details

Document Details

Form
DEF 14A
Filing Date
April 26, 2024
Document Date
April 26, 2024
Form Description
Official notification to shareholders of matters to be brought to a vote ("Proxy")
Filing Group
Proxy Filings
Company
Axsome Therapeutics, Inc.
Issuer
Axsome Therapeutics, Inc.

Filing Formats

iXBRL
View HTML
Download PDF
Download DOC
Download XLS

XBRL

XBRL Viewer
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
XML - XBRL INSTANCE DOCUMENT
  • About Axsome
    • All
    • Overview
    • Management Team
    • Board of Directors
    • Intellectual Property
    • State Disclosures
  • Portfolio
    • All
    • Products Overview
    • Products Overview
    • Auvelity™ (dextromethorphan-bupropion)
    • Sunosi® (solriamfetol)
    • Symbravo® (meloxicam and rizatriptan)
    • Pipeline Overview
    • AXS‑05
    • AXS‑12
    • AXS‑14
  • Conditions
    • All
    • Overview
    • Depression
    • Migraine
    • Alzheimer's
      Disease Agitation
    • Excessive Daytime
      Sleepiness
    • Narcolepsy
    • Fibromyalgia
    • Smoking Cessation
  • Science
    • All
    • Overview
    • Medical Information U.S.
    • Medical Information International
    • Publications
  • Investors
    • All
    • Overview
    • Corporate Governance
    • Stock Information
    • Financial Information
    • News & Events
    • Webcasts &
      Presentations
    • Analyst Coverage
    • Shareholder Services
  • Careers
    • All
    • Careers
    • Current Opportunities
Axsome
  • Contact Us
  • Privacy Notice
  • Terms of Use
  • See Axsome Therapeutics on LinkedIn

AXSOME and its logos are trademarks or registered trademarks of Axsome Therapeutics,Inc. or its affiliates. Other trademarks are property of their respective owners.

© 2026 Axsome Therapeutics, Inc. All rights reserved. One World Trade Center, New York, NY, 10007 info@axsome.com